Simultaneous Quantification of 17 Cannabinoids by LC-MS-MS in Human Plasma.
Journal
Journal of analytical toxicology
ISSN: 1945-2403
Titre abrégé: J Anal Toxicol
Pays: England
ID NLM: 7705085
Informations de publication
Date de publication:
21 Apr 2022
21 Apr 2022
Historique:
received:
31
01
2021
revised:
09
03
2021
accepted:
22
03
2021
pubmed:
24
3
2021
medline:
23
4
2022
entrez:
23
3
2021
Statut:
ppublish
Résumé
In recent years, the surge in use of tetrahydrocannabinol (THC) and cannabidiol (CBD) has increased the need for sensitive and specific analytical assays to measure the said compounds in patients, to establish dose-effect relationships and to gain knowledge of their pharmacokinetics and metabolism. We developed and validated an online extraction high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) method for simultaneous quantification of 17 cannabinoids and metabolites including THC and its metabolites, CBD and its metabolites and other minor cannabinoids in human plasma. CBD-glucuronide (CBD-gluc) standard was produced in-house by isolation of CBD-gluc from urine of patients using pure CBD oil. For calibration standards and quality control samples, human plasma was spiked with cannabinoids at varying concentrations within the working range of the respective compound and 200 µL of the plasma was extracted using a simple one-step protein precipitation procedure. The extracts were analyzed using online trapping LC/LC-atmospheric pressure chemical ionization-MS-MS running in the positive multiple reaction monitoring mode. The lower limit of quantification ranged from 0.78 to 7.8 ng/mL, and the upper limits of quantification were between 100 and 2,000 ng/mL. Inter-day analytical accuracy and imprecision ranged from 90.4% to 111% and from 3.1% to 17.4%, respectively. The analysis of plasma samples collected during clinical studies showed that (3R-trans)-cannabidiol-7-oic acid (7-CBD-COOH) was the major human metabolite with 5960% (59.6-fold) of CBD followed by 7-hydroxy-CBD (177%), CBD-gluc (157%) and 6α-hydroxy-CBD (39.8%); 6β-hydroxy-CBD was not detected in any of the samples. In the present study, we developed and validated a robust LC-MS-MS assay for the simultaneous quantification of cannabinoids and their metabolites, which has been used to measure >5,000 samples in clinical studies. Moreover, we were able to quantify CBD-gluc and showed that 7-CBD-COOH, 7-hydroxy-CBD and CBD-gluc are the major CBD metabolites in human plasma.
Identifiants
pubmed: 33754154
pii: 6180560
doi: 10.1093/jat/bkab030
doi:
Substances chimiques
Cannabinoids
0
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-392Subventions
Organisme : Colorado Department of Public Health and Environment
ID : A Randomized, Double-blind, Placebo-controlled Cro
Organisme : Colorado Department of Public Health and Environment
ID : Cannabidiol (CBD) and Pediatric Epilepsy (G.S. Wan
Organisme : Colorado Department of Public Health and Environment
ID : Use of Medicinal Cannabinoids as Adjunctive Treatm
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.